Lake Street analyst Thomas Flaten lowered the firm’s price target on Optinose ( OPTN ) to $17 from $45 and keeps a Buy rating on the shares, saying that “in part accounting for the recent 1-for-15 reverse stock split, we revised our $3 price target to $17″ after OptiNose delivered preliminary XHANCE revenue for Q4 of $22.4M, which was above the firm’s and consensus estimates.

Stay Ahead of the Market:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on OPTN: